Live feed08:00:00·92dNEWSReleasevia QuantisnowEnsysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute PainByQuantisnow·Wall Street's wire, on your screen.ENSC· Ensysce Biosciences Inc.Health Care
